@article{28ef710fa7cf40c8ba383e18be1dbf03,
title = "Chemokine receptor CCR5 in interferon-treated multiple sclerosis",
abstract = "OBJECTIVE: To study the relationship between CC chemokine receptor CCR5 expression and disease activity in multiple sclerosis (MS) patients treated with beta-interferon (IFN-beta). METHODS: The CCR5 Delta32 allele and a CCR5 promoter polymorphism associated with cell surface expression of CCR5 were analyzed in 109 patients with relapsing-remitting MS treated with IFN-beta who were followed clinically for 1 year. Cellular CCR5 expression was measured by flow cytometry. RESULTS: Patients with MS had a higher percentage of CCR5-positive monocytes than healthy controls. Increased monocyte expression of CCR5 correlated weakly with an increased short-term relapse risk but there was no relationship between CCR5 Delta32 allele and CCR5 promoter polymorphism genotypes and relapse risk. CONCLUSIONS: The results do not support a major role of CCR5 in the pathogenesis of relapses in MS patients treated with IFN-beta, but it is possible that monocyte CCR5 expression may be used as a marker of disease activity.",
keywords = "Adult, Biological Markers, Central Nervous System, DNA Mutational Analysis, Female, Gene Frequency, Genetic Markers, Genetic Predisposition to Disease, Genetic Screening, Genotype, Humans, Interferon-beta, Interferons, Male, Middle Aged, Monocytes, Multiple Sclerosis, Relapsing-Remitting, Mutation, Polymorphism, Genetic, Promoter Regions, Genetic, Receptors, CCR5",
author = "Sellebjerg, {Finn Thorup} and Kristiansen, {Thomas Birk} and P Wittenhagen and P Garred and J Eugen-Olsen and Frederiksen, {Jette Lautrup Battistini} and S{\o}rensen, {T L}",
year = "2007",
doi = "10.1111/j.1600-0404.2007.00826.x",
language = "English",
volume = "115",
pages = "413--8",
journal = "Acta Neurologica Scandinavica",
issn = "0001-6314",
publisher = "John Wiley and Sons Inc",
number = "6",
}